Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiopulmonary bypass components downclassification under consideration by FDA.

This article was originally published in The Gray Sheet

Executive Summary

CARDIOPULMONARY BYPASS CIRCUIT DEVICES DOWNCLASSIFICATION may be possible based on information already gathered by FDA to support reclassification for centrifugal blood pumps, according to the agency. FDA is exploring the use of device data and special controls already developed for downclassification of centrifugal blood pumps from Class III to Class II as the basis for downclassifying defoamers, arterial line blood filters, oxygenators, and pulsatile flow generators, which also are components of the cardiopulmonary bypass circuit.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005850

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel